205 related articles for article (PubMed ID: 27015251)
1. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
2. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
4. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
6. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
7. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
8. Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Bourret J; Koenig A
J Manag Care Spec Pharm; 2016 Mar; 22(3):209-18. PubMed ID: 27003550
[TBL] [Abstract][Full Text] [Related]
9. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
10. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
[TBL] [Abstract][Full Text] [Related]
11. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
12. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.
Atzinger CB; Guo JJ
Am Health Drug Benefits; 2017 Feb; 10(1):27-36. PubMed ID: 28465766
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
14. Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.
Shafrin J; Ganguli A; Gonzalez YS; Shim JJ; Seabury SA
J Manag Care Spec Pharm; 2016 Dec; 22(12):1472-1481. PubMed ID: 27882832
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
17. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
Ding Q; Shiltz D; Hossami D; Konieczny AM
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
[TBL] [Abstract][Full Text] [Related]
18. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
19. Association of out-of-pocket pharmacy costs with adherence to varenicline.
Suehs BT; Davis C; Galaznik A; Joshi AV; Zou KH; Patel NC
J Manag Care Spec Pharm; 2014 Jun; 20(6):592-600. PubMed ID: 24856597
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
